Seek Returns

BIO.B vs. RVMD: Bio-Rad Laboratories vs. Revolution Medicines Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Bio-Rad Laboratories (BIO.B) has more than two decades of public-market history since September 21, 1999, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
Profile ItemBIO.BRVMD
NameBio-Rad Laboratories, Inc. Class B Common StockRevolution Medicines, Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization10.49 billion USD37.27 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateSeptember 21, 1999February 13, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
RVMD
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
Total Return (1Y)27.69%167.61%
Total Return (3Y, Annualized)9.13%106.21%
Total Return (5Y, Annualized)-12.33%39.32%

Risk Profile

Drawdown History

BIO.B
RVMD
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Revolution Medicines (RVMD) trades around 2.14M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
Volatility (1Y, Annualized)30.96%68.69%
Beta (5Y)1.001.44
Max Drawdown (5Y)-70.74%-54.25%
Avg. Volume (3M)112.14M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
Sharpe Ratio (1Y)0.742.37
Sortino Ratio (1Y)1.104.98

Profitability

ROE (TTM)

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Rad Laboratories (BIO.B) reports 14.27%, ranking against industry peers normally.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
RVMD
-93.56%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Rad Laboratories (BIO.B) at 39.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
RVMD
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revolution Medicines (RVMD) reports a negative operating margin of -852.98%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Bio-Rad Laboratories (BIO.B) reports 9.46%, ranking against industry peers normally.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-852.98%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
RVMD
-852.98%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
ROE (TTM)14.27%-93.56%
ROA (TTM)1.50%-32.13%
Net Margin (TTM)39.45%0.00%
Operating Margin (TTM)9.46%-852.98%
Gross Margin (TTM)52.19%0.00%

Growth

Revenue Growth

Only one side can be read here: Bio-Rad Laboratories (BIO.B) reports revenue growth of 0.65%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Bio-Rad Laboratories (BIO.B) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
Revenue Growth (YoY)0.65%--
Revenue Growth (3Y CAGR)-2.68%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Bio-Rad Laboratories (BIO.B) at 3.18 and Revolution Medicines (RVMD) at 8.36 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max
25.13
Q3
12.13
RVMD
8.36
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Bio-Rad Laboratories (BIO.B) at 0.18 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max
1.42
Q3
0.65
RVMD
0.50
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
Current Ratio (MRQ)3.188.36
Debt / Equity (MRQ)0.180.50
Net Debt / EBITDA-0.73--

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Bio-Rad Laboratories (BIO.B) trades at 10.36 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RVMD
--
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): RVMD does not report P/E ratio, so it has no value marker; BIO.B is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 4.05 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 188.63 clears its benchmark range — RVMD looks notably rich on sales.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

188.63

RVMD
188.63
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile relative to book while Revolution Medicines (RVMD) at 15.51 prices above its industry range — a wide valuation gap against assets.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.51

RVMD
15.51
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Revolution Medicines (RVMD)
MetricBIO.BRVMD
P/E Ratio (TTM)10.36--
P/S Ratio (TTM)4.05188.63
P/B Ratio (MRQ)1.3815.51
Free Cash Flow Yield (TTM)2.59%-2.38%